<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623320</url>
  </required_header>
  <id_info>
    <org_study_id>20/40/515</org_study_id>
    <nct_id>NCT04623320</nct_id>
  </id_info>
  <brief_title>Validation of a 13C Glucose Breath Test to Quantify Insulin Resistance in Type 1 Diabetes Mellitus Compared With the Euglycaemic Clamp Test</brief_title>
  <acronym>BRECLAIR</acronym>
  <official_title>Validation of a 13C Glucose Breath Test to Quantify Insulin Resistance in Type 1 Diabetes Mellitus Compared With the Euglycaemic Clamp Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance can be assessed by the euglycaemic clamp technique. To date, this is the&#xD;
      golden standard, but it is not suited for clinical practice. A 13C glucose breath test will&#xD;
      be tested as a valid alternative. The curve of the exhaled 13C CO2 as a function of glucose&#xD;
      metabolism can be correlated to the curve of the glucose disposal rate obtained via the clamp&#xD;
      technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hyperinsulinemic-euglycemic clamp technique is the golden standard to assess insulin&#xD;
      resistance in type 1 diabetes subjects. The plasma insulin concentration is acutely raised&#xD;
      and maintained at 100 Î¼U/ml by a continuous infusion of insulin. Meanwhile, the plasma&#xD;
      glucose concentration is held constant at basal levels by a variable glucose infusion. When&#xD;
      the steady-state is achieved, the glucose infusion rate equals glucose uptake by all the&#xD;
      tissues in the body and is therefore a measure of tissue insulin sensitivity.&#xD;
&#xD;
      These data will be compared with the results of a 13C glucose breath test. Breath tests using&#xD;
      13C substrates are based on the principle that 13C CO2 in the exhaled breath can be measured&#xD;
      as a metabolic tracer.&#xD;
&#xD;
      Breath testing has a major advantage over the clamp test in that it can be performed&#xD;
      non-invasively and repeatedly without necessary supervision by medical staff.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Correlation of the 13C breath test with the golden standard</measure>
    <time_frame>one day</time_frame>
    <description>sensitivity and specificity analysis using linear regression</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>NAFLD+T1DM+</arm_group_label>
    <description>Subjects with type 1 diabetes and ultrasound-defined NAFLD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD-T1DM+</arm_group_label>
    <description>Subjects with type 1 diabetes without ultrasound-defined NAFLD</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>euglycaemic clamp test</intervention_name>
    <description>clamp test (golden standard) to determine insulin resistance</description>
    <arm_group_label>NAFLD+T1DM+</arm_group_label>
    <arm_group_label>NAFLD-T1DM+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>13C glucose breath test</intervention_name>
    <description>13C glucose breath test to compare with the golden standard</description>
    <arm_group_label>NAFLD+T1DM+</arm_group_label>
    <arm_group_label>NAFLD-T1DM+</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 diabetes subjects from the research facility's outpatient clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult type 1 diabetes patients&#xD;
&#xD;
          -  25/50 subjects with confirmed NAFLD (using ultrasound criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  gastric bypass surgery&#xD;
&#xD;
          -  cirrhosis&#xD;
&#xD;
          -  secondary cause of liver steatosis present&#xD;
&#xD;
          -  any cause which makes a 4-hour clamp impossible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Mertens, M.D.</last_name>
    <phone>+32 821 74 03</phone>
    <email>jonathan.mertens@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Braspenning, nurse</last_name>
    <phone>+32 821 40 02</phone>
    <email>Rie.Braspenning@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe De Block, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>euglycaemic clamp</keyword>
  <keyword>breath test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

